Do Traders Think Mersana Therapeutics Inc (MRSN) Can Keep Climbing Thursday?

Mersana Therapeutics Inc (MRSN) stock has risen 41.27% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Mersana Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MRSN!

See Full MRSN Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With MRSN Stock Today?

Mersana Therapeutics Inc (MRSN) stock is trading at $5.34 as of 9:43 AM on Thursday, Feb 29, an increase of $0.49, or 10% from the previous closing price of $4.85. The stock has traded between $5.23 and $5.94 so far today. Volume today is light. So far 151,020 shares have traded compared to average volume of 1,847,321 shares.

More About Mersana Therapeutics Inc

Mersana Therapeutics Inc is a clinical stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's product candidate, XMT-1536, is in a Phase 1 clinical trial in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana's platform to advance their ADC pipelines. Click Here to get the full Stock Report for Mersana Therapeutics Inc stock.